Get informed when a big investor buys or sells
+ FollowOvervalued by 109.2% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $306.85 Million |
|---|---|
| Enterprise Value | $326.35 Million |
| Earnings per Share | $-0.03 |
| Beta | 1.24 |
| Outstanding Shares | 1,382,223,000 |
| P/E Ratio | -5.64 |
|---|---|
| PEG | -2.17 |
| Price to Sales | - |
| Price to Book Ratio | -0.22 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.9 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | -0.37 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 0.00% |
|---|---|
| Total Invested | $19,657▼ 44.18% |
| Investors Holding | 5▼ 1.00% |
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humaniz...